Diabeton Mb In The Treatment Of Type 2 Diabetes Mellitus And Prevention Of Its Late Complications


O.M. Smirnova, I.V. Kononenko

FGU “Endocrinological scientific center of the health Ministry of the Russian Federation, Moscow
The article is dedicated to the role of sulfonylureas (SU), primarily gliclazide (Diabeton MR) in the treatment of type 2 diabetes mellitus (DM2), discusses their effects on the cardiovascular system. Data supporting the benefits of gliclazide in front of so-called old SU (glibenclamide, etc.) are presented. It is shown that in addition to pronounced hypoglycemic action gliclazide has an antioxidant property, ability to prevent development of micro- and macrovascular complications of DM2, including myocardial infarction and stroke. The antioxidant properties, the lack of effect on apoptosis provide gentle action of this drug on ?-cells, that is also a undeniable advantage of gliclazide.

Similar Articles


Бионика Медиа